The latest report by IMARC Group, titled "US Prostate Cancer Biomarkers Market Size, Share, Trends and Forecast by Type, Application, End Use, and Region, 2026-2034", offers a comprehensive analysis of the industry, which comprises insights on the US prostate cancer biomarkers market. The report also includes competitor and regional analysis.

US Prostate Cancer Biomarkers Market Size Overview and Growth Forecast (2026–2034)

The US prostate cancer biomarkers market size reached USD 1.33 Billion in 2025 and is expected to grow to USD 4.59 Billion by 2034, registering a CAGR of 14.74% during 2026–2034. Market growth is supported by the integration of artificial intelligence and machine learning in biomarker discovery and risk stratification, expansion of liquid biopsy technologies and non-invasive testing platforms, and FDA regulatory approvals combined with clinical guideline adoption driving standardization and reimbursement frameworks. As diagnostic developers continue to introduce novel biomarker tests tailored to evolving clinical needs, the US prostate cancer biomarkers market growth is expected to remain strong over the forecast period.

Key Market Statistics at a Glance

Base Year: 2025

Historical Years: 2020–2025

Forecast Period: 2026–2034

Market Size (2025): USD 1.33 Billion

Projected Size (2034): USD 4.59 Billion

Growth Rate: CAGR of 14.74%

Explore Growth Opportunities in the US Prostate Cancer Biomarkers Market Grab Your Sample Report for Evaluation:

https://www.imarcgroup.com/us-prostate-cancer-biomarkers-market/requestsample

Key Factors Driving the US Prostate Cancer Biomarkers Market

The rising prevalence of prostate cancer, which affects roughly one in eight American men during their lifetime, is one of the major factors supporting the US prostate cancer biomarkers market growth. Clinicians and diagnostic developers are increasingly focused on tests that improve upon the limitations of traditional PSA screening. Urinary biomarker tests such as PCA3, SelectMDx, ExoDx Prostate IntelliScore, and MyProstateScore are gaining clinical adoption as they provide convenient, non-invasive alternatives with enhanced diagnostic accuracy. In addition, increasing awareness around early detection, personalized treatment planning, and growing investment in liquid biopsy platforms continues to strengthen the US prostate cancer biomarkers market share across diagnostic and research settings.

US Prostate Cancer Biomarkers Market Segmentation and Industry Trends

The US prostate cancer biomarkers market analysis covers multiple biomarker types, applications, and end-use segments. Protein biomarkers continue to represent a key segment given their established role in early detection and disease monitoring, while genetic, cell-based, and metabolomic biomarkers are also witnessing growing clinical interest. Among the leading US prostate cancer biomarkers market trends are the increasing use of artificial intelligence in biomarker discovery, wider adoption of next-generation liquid biopsy platforms capable of monitoring treatment response in real time, and growing integration of biomarker testing into routine urology practice. These trends are encouraging diagnostic companies to expand their test portfolios and invest in clinical validation studies.

Challenges and Opportunities in the US Prostate Cancer Biomarkers Market

The market faces challenges such as reimbursement uncertainty, the high cost of advanced molecular testing, and the need for extensive clinical validation before broader adoption. However, these factors are encouraging companies to pursue FDA approvals and align with clinical guidelines to support standardization and payer coverage. There are also significant opportunities for companies offering non-invasive urinary and blood-based biomarker tests, AI-driven risk stratification tools, and companion diagnostics linked to targeted therapies. As clinical adoption continues to evolve, businesses investing in innovation, regulatory alignment, and physician education are well positioned to benefit from the continued US prostate cancer biomarkers market growth.

Future Outlook: What's Next for the US Prostate Cancer Biomarkers Market?

The outlook for the US prostate cancer biomarkers market remains highly positive, supported by continued innovation in molecular diagnostics, growing clinical guideline adoption, and rising demand for personalized treatment planning. Future US prostate cancer biomarkers market trends are expected to include greater use of AI-powered risk stratification, expansion of multi-marker panels, wider availability of liquid biopsy tests for disease monitoring, and stronger integration of biomarker data into electronic health records. Companies that focus on innovation, regulatory approval, and reimbursement alignment will be well placed to expand their US prostate cancer biomarkers market share and capitalize on long-term growth opportunities through 2034.

US Prostate Cancer Biomarkers Market Segmentation:

Type Insights:

•        Genetic Biomarkers

•        Protein Biomarkers

•        Cell-Based Biomarkers

•        Metabolomic Biomarkers

•        Others

Application Insights:

•        Screening and Early Detection

•        Diagnosis and Risk Stratification

•        Prognosis and Treatment Monitoring

•        Others

End Use Insights:

•        Hospitals

•        Diagnostic Laboratories

•        Research and Academic Institutes

•        Others

Regional Insights:

•        Northeast

•        Midwest

•        South

•        West

Speak to an Analyst: https://www.imarcgroup.com/request?type=report&id=43837&flag=C

Major Players Shaping the US Prostate Cancer Biomarkers Market

•        Abbott Laboratories – A leading diagnostics company offering high-throughput PSA and other immunoassay-based biomarker testing platforms used widely in clinical laboratories.

•        Thermo Fisher Scientific Inc. – Provides a broad portfolio of molecular diagnostics and genomic testing solutions supporting biomarker discovery and clinical research.

•        QIAGEN – Offers molecular testing technologies and sample-to-insight solutions supporting genetic and protein biomarker analysis.

•        Roche Diagnostics – Known for its Cobas and Elecsys PSA assay platforms, supporting widespread clinical adoption of prostate cancer screening tests.

•        Danaher Corporation (Beckman Coulter, Inc.) – Provides advanced immunoassay and diagnostic platforms supporting biomarker testing across hospital and laboratory settings.

•        Myriad Genetics, Inc. – Specializes in genetic and genomic testing solutions, including tests supporting personalized prostate cancer risk assessment.

Author IMARC Group

IMARC Group is a leading global management consulting firm providing comprehensive market research, feasibility studies, and strategic advisory services. The firm supports organizations worldwide in identifying growth opportunities, mitigating risks, and making informed business decisions across industries.

Contact Us

IMARC Group

Email: sales@imarcgroup.com

United States: +1-201-971-6302